0000000000643089

AUTHOR

Rocio Garcia Carbonero

showing 1 related works from this author

Phase 1 study of biweekly (Q2W) anti-EGFR monoclonal antibody (mAb) mixture Sym004 in patients (pts) with metastatic colorectal cancer (mCRC) resista…

2014

3551 Background: Preclinical models suggest that WT KRAS mCRC may retain EGFR dependency despite resistance developed to anti-EGFR mAb treatment (eg, cetuximab or panitumumab). Sym004 is the first-...

Cancer ResearchCetuximabColorectal cancermedicine.drug_classbusiness.industrymedicine.diseaseMonoclonal antibodymedicine.disease_causedigestive system diseasesOncologymedicineCancer researchPanitumumabIn patientKRASAnti-EGFR Monoclonal Antibodybusinessneoplasmsmedicine.drugJournal of Clinical Oncology
researchProduct